Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFZIL.
ANCEF IN PLASTIC CONTAINER vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic